Skip to main content
ABUS
NASDAQ Life Sciences

Arbutus Posts $59.1M Q3 Profit on Genevant Dividend, Expands Pfizer/BioNTech Patent Suits

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.71
Mkt Cap
$736.953M
52W Low
$3.5
52W High
$5.45
52W Position info
6.0% above low
Off High info
32% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ABUS is trading near its 52-week low of $3.5 (6.0% above the low) on light trading volume (0.3× avg).

Summary

Arbutus reported $59.1M of Q3 net income, driven mainly by a $67.3M Genevant dividend, and ended the quarter with $337.5M in cash and securities after its $230M buyback. The company also filed new LNP patent suits against Pfizer/BioNTech in Japan and amended its Canadian case.


Key Events · Earnings and Guidance · ABUS

  • Q3 Net Income of $59.1M

    Net income was $59.1M, or $0.30 per basic and diluted share, versus a $7.7M net loss in Q3 2025; the swing was driven by a $67.3M Genevant dividend.

  • Cash Position of $337.5M

    Cash, cash equivalents and marketable securities totaled $337.5M as of September 30, 2026, up from $91.5M at December 31, 2025, after the $230M tender offer.

  • New Pfizer/BioNTech Patent Suits

    Arbutus and Genevant filed two Tokyo District Court suits (Japanese Patent Nos. 5,475,753 and 7,936,499) and amended the Canadian case to add Canadian Patent No. 2,767,127.

  • Moderna Appeal Argument Held

    Expedited oral argument on the Moderna §1498 appeal was held November 5, 2026 at the Federal Circuit; a decision is forthcoming and could trigger the additional $1.3B contingent payment.


Analysis · ABUS · Life Sciences

The quarter's profit rests largely on a $67.3M Genevant dividend rather than operating income, so the headline number overstates the underlying business. More telling is the balance sheet: $337.5M of cash and securities after returning $230M to shareholders via the tender offer, which funds the imdusiran and AB-101 programs for years. Meanwhile, new Japan lawsuits and an amended Canadian case widen the Pfizer/BioNTech LNP enforcement effort, and the Federal Circuit's forthcoming ruling on the Moderna §1498 appeal could unlock the additional $1.3B contingent payment.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABUS was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $737M. The 52-week trading range was $3.50 to $5.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABUS - Latest Insights

ABUS
Nov 10, 2026, 7:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.71 info
Change: $0 (0%) info
Market Cap: $736.953M info
ABUS
Oct 22, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $3.71 info
Change: -$0.540 (-13%) info
Market Cap: $736.953M info
ABUS
Oct 22, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.24
Real-time Price: $3.71 info
Change: -$0.5297 (-12%) info
Market Cap: $736.953M info
ABUS
Sep 30, 2026, 7:35 AM EDT
Filing Type: SC TO-I/A
Importance Score:
7
Price at Filing: $4.66
Real-time Price: $3.71 info
Change: -$0.9528 (-20%) info
Market Cap: $736.953M info
ABUS
Aug 24, 2026, 8:24 AM EDT
Filing Type: SC TO-I
Importance Score:
7
Price at Filing: $5.21
Real-time Price: $3.71 info
Change: -$1.50 (-29%) info
Market Cap: $736.953M info